Medbright Ai Invts Inc. (MBAIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medbright Ai Invts Inc. (MBAIF) trades at $0.14. MedBright AI invests in healthcare technology companies, aiming for superior returns through strategic capital allocation. Market cap: $31.83M, Sector: Consumer defensive.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for MBAIF: MBAIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MBAIF against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MBAIF: 1/1 perspectives are bearish.
How is this calculated? →Medbright Ai Invts Inc. (MBAIF) Consumer Business Overview
MedBright AI is a capital allocator focused on healthcare technology investments, seeking high-quality, synergistic opportunities. With a commitment to governance and a focus on near-to-mid-term returns, the company aims to deliver superior shareholder value within the Consumer Defensive sector, leveraging its access to unique investment prospects.
What Is the Investment Thesis for MBAIF?
MedBright AI presents an investment opportunity predicated on its strategic focus within the healthcare technology sector. With a market capitalization of $31.83M and a P/E ratio of 3.8, the company's financial profile suggests potential for growth. A key value driver is the company's ability to identify and secure advantageous investment opportunities, leading to enhanced returns. Ongoing catalysts include the continued expansion of the healthcare technology market and MedBright AI's ability to capitalize on emerging trends. Potential risks include the inherent volatility of the OTC market and the company's reliance on successful execution of its investment strategy. The company's high profit margin of 296.8% suggests strong profitability from its investments.
Based on FMP financials and quantitative analysis
MBAIF Key Highlights
- Market capitalization of $31.83M indicates a relatively small but potentially high-growth company.
- P/E ratio of 3.8 suggests the company may be undervalued compared to its earnings.
- Profit margin of 296.8% demonstrates strong profitability from its investments.
- Gross margin of 9.8% reflects the company's efficiency in generating revenue from its investments.
- Beta of 1.35 indicates the stock is more volatile than the market, potentially offering higher returns but also higher risk.
Who Are MBAIF's Competitors?
MBAIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BFNH BioForce Nanosciences Holdings, Inc. | $1.96 | -3.45% | $65.76M | 42 |
| CFOO China Foods Holdings Ltd. | $0.66 | +0.00% | $13.45M | 44 |
| DWWEF Diamond Estates Wines & Spirits Inc. | $0.11 | -7.76% | $7.36M | 41 |
| EXDW Exceed World, Inc. | $0.29 | +0.00% | $9.56M | 53 |
| AIU Meta Data Limited | $0.61 | +2.50% | $37.56M | 64 |
| PRDO Perdoceo Education Corporation | $34.43 | +3.55% | $2.16B | 62 |
| TAL TAL Education Group | $9.89 | +0.87% | $6.02B | 62 |
| GOTU Gaotu Techedu Inc. | $1.75 | -0.29% | $632.99M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MBAIF's Key Strengths?
- Strong profit margin of 296.8%.
- Focus on high-growth healthcare technology sector.
- Experienced management team with access to unique opportunities.
- Commitment to governance and risk management.
What Are MBAIF's Weaknesses?
- Small market capitalization of $31.83M.
- OTC listing may limit liquidity and investor access.
- Reliance on successful execution of investment strategy.
- Limited financial disclosure due to OTC status.
What Could Drive MBAIF Stock Higher?
- Expansion into new healthcare technology sub-sectors, such as telehealth and AI-powered diagnostics.
- Strategic partnerships with established healthcare providers to facilitate technology adoption.
- Geographic expansion into international markets with high growth potential.
- Potential for increased investment in AI-driven healthcare solutions.
- Development of a proprietary investment platform to streamline investment processes.
What Are the Key Risks for MBAIF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger and more established investment firms in the healthcare technology sector.
- Regulatory changes impacting the healthcare technology sector, such as data privacy regulations.
- Economic downturn affecting investment returns and the availability of capital.
- Volatility of the OTC market and limited liquidity of MBAIF stock.
- Lack of financial disclosure and transparency due to OTC listing.
What Are the Growth Opportunities for MBAIF?
- Expansion into new healthcare technology sub-sectors: MedBright AI can explore investment opportunities in emerging areas such as telehealth, digital therapeutics, and AI-powered diagnostics. The global telehealth market is projected to reach $55.6 billion by 2027, presenting a significant growth opportunity. By diversifying its investments across these sub-sectors, MedBright AI can mitigate risk and capitalize on the diverse growth drivers within the healthcare technology landscape. This expansion can be achieved within the next 1-3 years.
- Strategic partnerships with established healthcare providers: Collaborating with hospitals, clinics, and other healthcare organizations can provide MedBright AI with access to a broader network of investment opportunities and potential synergies. These partnerships can facilitate the adoption of innovative technologies and drive revenue growth for MedBright AI's portfolio companies. The timeline for establishing these partnerships is estimated at 1-2 years, with ongoing benefits accruing over the long term. This will also help with market validation of the technologies.
- Geographic expansion into new markets: MedBright AI can explore investment opportunities in international markets with high growth potential in healthcare technology, such as Asia-Pacific and Europe. These markets offer access to a diverse range of innovative companies and technologies. The timeline for geographic expansion is estimated at 2-3 years, requiring careful consideration of regulatory and cultural factors. This expansion can significantly increase the company's reach and potential returns.
- Increased investment in AI-driven healthcare solutions: Given the company's name and focus, MedBright AI can further capitalize on the growing adoption of artificial intelligence in healthcare. This includes investing in companies developing AI-powered diagnostic tools, personalized treatment plans, and drug discovery platforms. The AI in healthcare market is projected to reach $34 billion by 2025, presenting a significant growth opportunity. This strategy aligns with the company's core competencies and can drive long-term value creation.
- Development of a proprietary investment platform: MedBright AI can develop a technology platform to streamline its investment process, improve data analysis, and enhance decision-making. This platform can leverage AI and machine learning to identify promising investment opportunities and optimize portfolio performance. The development of this platform is estimated at 1-2 years, with ongoing enhancements and updates. This will improve efficiency and scalability of their operations.
What Opportunities Does MBAIF Have?
- Expansion into new healthcare technology sub-sectors.
- Strategic partnerships with established healthcare providers.
- Geographic expansion into new markets.
- Increased investment in AI-driven healthcare solutions.
What Threats Does MBAIF Face?
- Competition from larger and more established investment firms.
- Regulatory changes impacting the healthcare technology sector.
- Economic downturn affecting investment returns.
- Volatility of the OTC market.
What Are MBAIF's Competitive Advantages?
- Unparalleled access to investment opportunities.
- Expertise in structuring unique and advantageous investments.
- Synergistic portfolio of healthcare technology companies.
- Commitment to governance and risk management.
What Does MBAIF Do?
MedBright AI Invts Inc., based in Vancouver, Canada, operates as a capital allocator with a specific focus on investing in healthcare technology companies. Founded on the principle of identifying and structuring unique and advantageous investments, MedBright AI aims to build a portfolio of synergistic assets that generate superior returns for its shareholders. The company's strategy centers on targeting high-quality opportunities with strong return potential in the near and mid-term, while maintaining a strong commitment to corporate governance. MedBright AI's approach involves leveraging its team's access to investment opportunities within the rapidly evolving healthcare technology sector. By carefully selecting and structuring its investments, MedBright AI seeks to capitalize on the growth and innovation occurring within this space. The company's mission is to create a diversified portfolio that not only delivers financial returns but also contributes to advancements in healthcare technology. With 366 employees, MedBright AI is positioned to execute its investment strategy and drive value for its shareholders.
What Products and Services Does MBAIF Offer?
- Invest in healthcare technology companies.
- Allocate capital to synergistic opportunities.
- Structure unique and advantageous investments.
- Generate superior returns for shareholders.
- Focus on near and mid-term high-quality opportunities.
- Maintain commitment to governance.
How Does MBAIF Make Money?
- Identify promising healthcare technology companies.
- Invest capital in exchange for equity or other financial instruments.
- Provide strategic guidance and support to portfolio companies.
- Generate returns through capital appreciation and dividends.
What Industry Does MBAIF Operate In?
MedBright AI operates within the Consumer Defensive sector, specifically in the Education & Training Services industry, focusing on healthcare technology investments. The healthcare technology market is experiencing rapid growth, driven by technological advancements, increasing healthcare expenditures, and a growing demand for innovative solutions. MedBright AI's competitive landscape includes companies such as BFNH, CFOO, DWWEF, EXDW, and GLGLF, each vying for opportunities in the healthcare technology space. MedBright AI differentiates itself through its focus on synergistic investments and commitment to governance.
Who Are MBAIF's Key Customers?
- Shareholders seeking returns on investment.
- Healthcare technology companies seeking capital and expertise.
- Healthcare providers seeking innovative solutions.
- Patients benefiting from advancements in healthcare technology.
Medbright Ai Invts Inc. Financial Trajectory
Medbright Ai Invts Inc. (MBAIF) reported $114K in revenue for Q3 2025, based on the latest filing compared to the prior quarter. The company recorded net income of $347K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Consumer Defensive. Across the four most recent quarters, MBAIF averaged $-0.07 in diluted EPS.
Company Profile
Medbright Ai Invts Inc. operates in the Education & Training Services industry within the Consumer Defensive sector. It is headquartered in Vancouver, CA. The company is led by CEO Yam-Chung Chu. MBAIF has traded publicly since 2007.
How Medbright Ai Invts Inc. Is Valued
Medbright Ai Invts Inc. carries a market capitalization of $31.83M, placing it in the micro-cap category.
ROE 194%Key Financial Metrics
Return on equity for Medbright Ai Invts Inc. stands at 194.3%, a gauge of how efficiently it converts shareholder capital into profit. MBAIF trades at a trailing price-to-earnings ratio of 3.76, below the Consumer Defensive sector average of ~29x. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 23.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Medbright Ai Invts Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 63.54 places it in the safe zone, indicating low near-term bankruptcy risk.
MBAIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Medbright's future prospects, indicating that those closest to the company believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative advancements in AI technology that Medbright is pursuing.
- Analysts have noted increasing interest in AI-driven healthcare solutions, positioning Medbright favorably within a rapidly growing market.
- The company's recent partnerships with healthcare providers have generated buzz, suggesting a solid strategic direction and potential for revenue growth.
Bear Case
- Concerns have arisen regarding the competitive landscape, as larger players in the AI healthcare space continue to dominate discussions and attract investment.
- Some community members express skepticism about Medbright's ability to scale its technology effectively, fearing it may not keep pace with industry leaders.
- Recent regulatory scrutiny on AI applications in healthcare has raised questions about compliance and potential delays in product deployment for Medbright.
- There are lingering doubts about the company's financial sustainability, with discussions reflecting worries over funding and operational costs in a challenging economic environment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $113,963 | $347,172 | $0.0043 |
| Q2 2025 | $0 | -$489,156 | -$0.0044 |
| Q1 2025 | $0 | $5M | $0.09 |
| Q4 2024 | $0 | -$4M | -$0.36 |
Based on FMP financials and quantitative analysis
MBAIF Latest News
No recent news available for MBAIF.
MBAIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MBAIF.
Price Targets
Wall Street price target analysis for MBAIF.
MBAIF MoonshotScore
What does this score mean?
The MoonshotScore rates MBAIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Education & Training ServicesLeadership: Yam-Chung Chu
Managing
Yam-Chung Chu is the managing leader at MedBright AI Invts Inc., overseeing a team of 366 employees. Information regarding Yam-Chung Chu's detailed career history, educational background, and previous roles is not available in the provided data. However, as the leader of MedBright AI, Yam-Chung Chu is responsible for guiding the company's strategic direction and investment decisions within the healthcare technology sector.
Track Record: Due to limited information, specific achievements, strategic decisions, and company milestones under Yam-Chung Chu's leadership cannot be detailed. However, the company's focus on synergistic investments and commitment to governance suggest a strategic approach aimed at long-term value creation.
MBAIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MedBright AI may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to companies on regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing.
- Lack of financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher volatility compared to stocks on major exchanges.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor to assess the suitability of the investment.
- Check for any regulatory actions or legal proceedings against the company.
- Confirm the company's contact information and physical address.
- Positive profit margin of 296.8% suggests a viable business model.
- Focus on the high-growth healthcare technology sector.
- Commitment to governance and risk management.
- Presence of a management team overseeing operations.
What Investors Ask About Medbright Ai Invts Inc. (MBAIF) — Consumer Defensive
What does Medbright Ai Invts Inc. do?
MedBright AI operates as a capital allocator focused on investing in healthcare technology companies. The company identifies and invests in synergistic opportunities within the healthcare technology sector, aiming to generate superior returns for its shareholders. MedBright AI's strategy involves targeting high-quality opportunities with strong return potential in the near and mid-term, while maintaining a strong commitment to corporate governance. The company leverages its team's access to investment opportunities to build a diversified portfolio of healthcare technology assets.
What are the main risks for MBAIF?
The main risks for MedBright AI include the volatility and limited liquidity associated with its OTC listing. The company's reliance on successful execution of its investment strategy also poses a risk, as does competition from larger and more established investment firms. Regulatory changes impacting the healthcare technology sector and the lack of financial disclosure due to OTC status are also significant risks to consider. These factors could impact the company's ability to generate returns and create value for shareholders.
What are the key factors to evaluate for MBAIF?
Evaluate MBAIF on fundamentals, analyst consensus, and risk factors. P/E: 3.8x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does MBAIF data refresh on this page?
MBAIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MBAIF's recent stock price performance?
Medbright Ai Invts Inc. (MBAIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong profit margin of 296.8%. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MBAIF overvalued or undervalued right now?
Medbright Ai Invts Inc. (MBAIF) trades at 3.8x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MBAIF?
Before investing in Medbright Ai Invts Inc. (MBAIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MBAIF to a portfolio?
Key strength of Medbright Ai Invts Inc. (MBAIF): Strong profit margin of 296.8%. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Lack of analyst coverage and price targets.
- Financial data based on available information and may not be comprehensive.